menu
    • menu
    [{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Eganelisib","moa":"PI3K-gamma","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ BVF Partners L.P","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ BVF Partners L.P"},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apilimod mesylate","moa":"PIKfyve kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kintai Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintai Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Flerie Invest AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"DSP107","moa":"SIRP alpha\/41BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Kahr Medical \/ Flerie Invest AB","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Flerie Invest AB"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Temasek","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series D Financing","leadProduct":"SQZ-PBMC-HPV","moa":"CD8 T-Cell","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Temasek","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotechnologies \/ Temasek"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"RO7198457","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"DKN-01","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Piper Sandler & Co"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PRS-343","moa":"CD137","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PRS-343","moa":"CD137","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"DSP107","moa":"SIRP alpha\/41BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kahr Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Halozyme Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Efineptakin alfa","moa":"IL-7","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"F. Hoffmann-La Roche \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ NeoImmuneTech"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"SQZ-PBMC-HPV","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ BofA Securities"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Oncolytics Biotech","highestDevelopmentStatusID":"1","companyTruncated":"F. Hoffmann-La Roche \/ Oncolytics Biotech"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"SB 11285","moa":"STING pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ SOLTI"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"SQZ-PBMC-HPV","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"DSP107","moa":"SIRP alpha\/41BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kahr Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Not Applicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Genentech"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ SOLTI"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Atezolizumab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kleo Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Kleo Pharmaceuticals \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Kleo Pharmaceuticals \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"UCLA Jonsson Comprehensive Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"UCLA Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"UCLA Jonsson Comprehensive Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCLA Jonsson Comprehensive Cancer Center \/ Not Applicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Piper Sandler & Co","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Piper Sandler & Co"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Natera","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Natera \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Natera \/ Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"SB 11285","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Uliledlimab","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Uliledlimab","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"DSP107","moa":"CD47x41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ aMoon","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ aMoon"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"SB 11285","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Syros Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Immunicom","sponsor":"Acibadem University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Immunicom","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immunicom \/ Acibadem University","highestDevelopmentStatusID":"12","companyTruncated":"Immunicom \/ Acibadem University"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"University of Rochester","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hard Gelation Capsule","sponsorNew":"Pharmaxis \/ University of Rochester","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ University of Rochester"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Mosunetuzumab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"City of Hope \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"City of Hope \/ Not Applicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SQZ-PBMC-HPV","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Oncocyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncocyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncocyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncocyte \/ Not Applicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"HPN328","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI-Innovative Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI-Innovative Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ SOLTI-Innovative Cancer Research"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VB10.16","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nykode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Imago BioSciences \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Imago BioSciences \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Uliledlimab","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Not Applicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GRT-C901","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"ImaginAb","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Autogene Cevumeran","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mosunetuzumab","moa":"CD20\/CD3","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Galecto","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"PTK","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mosunetuzumab","moa":"CD20\/CD3","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SQZ-PBMC-HPV","moa":"CD8 T-Cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"GRT-C901","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Hercules Capital"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CYTO-102","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"CEND-1","moa":"Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lisata Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Arbele","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ARB202","moa":"CDH17","graph1":"Oncology","graph2":"Phase I","graph3":"Arbele","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arbele \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbele \/ Not Applicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Not Applicable"},{"orgOrder":0,"company":"Gradalis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Gemogenovatucel-T","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gradalis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"Tyrosine kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Gradalis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Gemogenovatucel-T","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gradalis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Uliledlimab","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Private Placement","leadProduct":"GRT-C901","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Redmile Group"},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mosunetuzumab","moa":"CD20\/CD3","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM20059","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VB10.16","moa":"APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Replimune","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Genetically Modified HSV-1","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replimune \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Replimune \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMC-C103C","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Genentech"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GRT-C901","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Not Applicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"ADG126","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Suzhou Limited \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"VB10.16","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mosunetuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mosunetuzumab-axg","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"NP137","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"NETRIS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NETRIS Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NETRIS Pharma \/ Not Applicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Humanized Claudin18.2 Monoclonal Antibody","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"VB10.16","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ GOG Foundation"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VB10.16","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TPST-1120","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TPST-1120","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Adagene Suzhou Limited","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Adagene Suzhou Limited"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AB011","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"VB10.16","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DSP107","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Not Applicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"SRF388","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Coherus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Coherus Biosciences"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Arbele","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arbele","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbele \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbele \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HTL0039732","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sosei Heptares \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Sosei Heptares \/ Cancer Research"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SON-1010","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Casdozokitug","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Coherus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Coherus Biosciences"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"HPN328","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TPST-1120","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Autogene Cevumeran","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Genentech"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"HPN328","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Soleus Capital","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Soleus Capital"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"IL12-FHAB","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"NKT2152","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NiKang Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"HPN328","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"IO-108","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"MK-6070","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"XTX101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Autogene Cevumeran","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Not Applicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"PT217","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tiragolumab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amezalpat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"MK-6070","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amezalpat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"LB-100","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"TPST-1120","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Vilastobart","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amezalpat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"IL12-FHAB","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PPAR alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Vilastobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27","graph1":"Oncology","graph2":"Phase II","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NKT2152","moa":"||HIF2\u03b1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Quaratusugene Ozeplasmid","moa":"||TUSC2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PPAR alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IO-108","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Immunomedics","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Immunomedics"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ZL-1310","moa":"||DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Atezolizumab

    Menu

    Atezolizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immune-Onc Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Immune-Onc Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IO-108,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immune-Onc Doses First Patient in IO-108 Phase 1b/2 Liver Cancer Study

                            Details : IO-108 antibody is being evaluated in combination with atezolizumab and bevacizumab for the treatment of locally advanced hepatocellular carcinoma.

                            Product Name : IO-108

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 27, 2025

                            Lead Product(s) : IO-108,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rznomics

                            South Korea arrow
                            BePharma
                            Not Confirmed

                            Rznomics

                            South Korea arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RZ-001,Valganciclovir Hydrochloride,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rznomics Inc. Liver Cancer Drug Candidate Secures Fast Track Designation

                            Details : RZ-001 is an anti-HCC activity by suppressing hTERT expression selectively in cancer cells. It is being in combination with valganciclovir for the treatment of hepatocellular carcinoma.

                            Product Name : RZ-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : RZ-001,Valganciclovir Hydrochloride,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genprex

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Genprex

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genprex Doses First Patient in Phase 2 Expansion of Acclaim-3 Trial in SCLC

                            Details : Reqorsa Immunogene therapy (quaratusugene ozeplasmid), which is currently being investigated in combination with Tecentriq for extensive-stage small cell lung cancer.

                            Product Name : Reqorsa

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Coherus Biosciences

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Coherus Biosciences

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Casdozokitug,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Coherus Presents Phase 2 Data for Casdozokitug in Hepatocellular Carcinoma

                            Details : Casdozo (casdozokitug), a selective and potent IL-27-targeting antibody, in combination with atezolizumab and bevacizumab in patients with unresectable locally advanced or metastatic HCC.

                            Product Name : Casdozo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : Casdozokitug,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zai Lab

                            China arrow
                            BePharma
                            Not Confirmed

                            Zai Lab

                            China arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZL-1310,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zai Lab Gets Orphan Drug Designation for ZL-1310 in Small Cell Lung Cancer

                            Details : ZL-1310 is an innovative Antibody-Drug-Conjugate targeting DLL3, it is being developed as a promising therapeutic target in small cell lung cancer and other DLL3+ solid tumors.

                            Product Name : ZL-1310

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : ZL-1310,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xilio Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Xilio Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vilastobart,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xilio Therapeutics Announces Phase 2 Data for Vilastobart in Colorectal Cancer

                            Details : XTX101 (vilastobart) is an antibody infusion therapy inhibiting CTLA-4, is being investigated for the treatment of microsatellite stable colorectal cancer in combination with Atezolizumab.

                            Product Name : XTX101

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : Vilastobart,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            NiKang Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            NiKang Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKT2152,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NiKang Doses First Patient in Phase 1b/2 Study of NKT2152 for Hepatocellular Carcinoma

                            Details : NKT2152, a highly potent, selective & orally bioavailable small molecule HIF2α inhibitor, in combination with standard-of-care in the first-line treatment of patients with advanced or metastatic HCC.

                            Product Name : NKT2152

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : NKT2152,Atezolizumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tempest Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Tempest Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amezalpat,Bevacizumab,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tempest’s Amezalpat Receives FDA Orphan Drug Designation for HCC

                            Details : TPST-1120 (amezalpat) target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a combination with atezolizumab and bevacizumab.

                            Product Name : TPST-1120

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Amezalpat,Bevacizumab,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Affimed

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Affimed

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AFM24,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Affimed Updates On AFM24 Combo with Atezolizumab in NSCLC Therapy

                            Details : AFM24 is a tetravalent, bispecific innate cell engager that binds to CD16A. It is being evaluated for the treatment of EGFR-Wildtype Non-Small Cell Lung Cancer.

                            Product Name : AFM24

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 17, 2024

                            Lead Product(s) : AFM24,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Genprex

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Genprex

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genprex Advances Reqorsa® Gene Therapy To Phase 2 for Small Cell Lung Cancer

                            Details : Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) is being investigated in combination with Tecentriq for extensive-stage small cell lung cancer.

                            Product Name : Reqorsa

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 16, 2024

                            Lead Product(s) : Quaratusugene Ozeplasmid,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth